Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F17%3A43913023" target="_blank" >RIV/00216208:11120/17:43913023 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064173:_____/17:N0000027

Výsledek na webu

<a href="http://dx.doi.org/10.1200/JCO.2016.71.3289" target="_blank" >http://dx.doi.org/10.1200/JCO.2016.71.3289</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1200/JCO.2016.71.3289" target="_blank" >10.1200/JCO.2016.71.3289</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials

Popis výsledku v původním jazyce

Purpose: Clinical characteristics, therapeutic approaches, and prognosis of late relapse (LR) in patients with classic Hodgkin lymphoma (cHL) are poorly understood. We performed a comprehensive analysis of LR of Hodgkin lymphoma (LR-HL). Methods. To estimate the incidence of LR-HL, we retrospectively analyzed 6,840 patients with cHL included in the German Hodgkin Study Group trials HD7 to HD12. Patients who experienced a relapse &gt;5 years into remission were compared with patients in continued remission for &gt;5 years and with those who experienced a relapse &lt;= 5 years after first diagnosis. Conclusion. Apart from treatment-associated adverse effects, survivors after initially successful therapy for cHL are at an 85-fold risk for recurrence of disease compared with the general German population. After risk-adapted treatment strategies, especially in early-stage favorable HL, regular clinical follow-up is recommended for timely detection of LR-HL. With adequate treatment, prognosis of LR-HL is better compared with early relapses. (C) 2017 by American Society of Clinical Oncology

Název v anglickém jazyce

Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials

Popis výsledku anglicky

Purpose: Clinical characteristics, therapeutic approaches, and prognosis of late relapse (LR) in patients with classic Hodgkin lymphoma (cHL) are poorly understood. We performed a comprehensive analysis of LR of Hodgkin lymphoma (LR-HL). Methods. To estimate the incidence of LR-HL, we retrospectively analyzed 6,840 patients with cHL included in the German Hodgkin Study Group trials HD7 to HD12. Patients who experienced a relapse &gt;5 years into remission were compared with patients in continued remission for &gt;5 years and with those who experienced a relapse &lt;= 5 years after first diagnosis. Conclusion. Apart from treatment-associated adverse effects, survivors after initially successful therapy for cHL are at an 85-fold risk for recurrence of disease compared with the general German population. After risk-adapted treatment strategies, especially in early-stage favorable HL, regular clinical follow-up is recommended for timely detection of LR-HL. With adequate treatment, prognosis of LR-HL is better compared with early relapses. (C) 2017 by American Society of Clinical Oncology

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Clinical Oncology

ISSN

0732-183X

e-ISSN

—

Svazek periodika

35

Číslo periodika v rámci svazku

13

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

1444-1450

Kód UT WoS článku

000400335500010

EID výsledku v databázi Scopus

2-s2.0-85018347722